Comparative Pharmacology
Head-to-head clinical analysis: FOLLISTIM AQ versus PERGONAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLLISTIM AQ versus PERGONAL.
FOLLISTIM AQ vs PERGONAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased cAMP production.
Pergonal (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from postmenopausal urine. It stimulates ovarian follicular growth and maturation in women and spermatogenesis in men by acting on specific gonadal receptors.
75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.
Intramuscular administration: 75 IU daily for 7-12 days, then 5,000-10,000 IU hCG 24 hours after last dose.
None Documented
None Documented
Terminal elimination half-life approximately 24-36 hours (subcutaneous route); clinical context supports daily dosing due to sustained follicular stimulation.
Terminal elimination half-life approximately 24-36 hours; clinical context: supports daily dosing in ovulation induction protocols.
Primarily renal (90%), with intact follitropin alfa/beta and metabolites excreted in urine; biliary/fecal excretion minimal (<10%).
Primarily renal: 70-80% as unchanged drug and metabolites within 24 hours; biliary/fecal excretion accounts for <5%.
Category C
Category C
Gonadotropin
Gonadotropin